Author:
Karadi Rangaprasad L,Gow David,Kellett Mark,Denning David W,O'Driscoll Ronan B
Abstract
Abstract
Introduction
Itraconazole is an anti-fungal agent widely used to treat various forms of mycosis. It is particularly useful in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. Side effects are uncommon and usually mild. Mild neuropathy is noted to occur very rarely. We present an unusual and, to the best of our knowledge, as yet unreported case of severe neuropathy and peripheral edema due to itraconazole in the absence of a concomitant risk factor.
Case presentation
A 72-year-old Caucasian man was started on itraconazole following diagnosis of severe asthma with fungal sensitization. One month later he presented with severe bilateral ankle edema with an elevated serum itraconazole level. The itraconazole dose was reduced but his ankle edema persisted and he developed weakness of all four limbs. Itraconazole was completely stopped leading to improvement in his leg edema but he became bed bound due to weakness. He gradually improved with supportive care and neurorehabilitation. On review at six months, our patient was able to mobilize with the aid of two elbow crutches and power had returned to 5/5 in distal extremities and 4+/5 in proximal extremities. The diagnosis was established based on the classical presentation of drug-induced neuropathy and negative investigatory findings for any alternative diagnoses.
Conclusion
We report the case of a patient presenting with an unusual complication of severe neuropathy and peripheral edema due to itraconazole. Clinicians should be alert to this association when encountered with neuropathy and/or edema in an itraconazole therapy recipient.
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Polak A: Antifungal therapy - state of the art at the beginning of the 21st century. Prog Drug Res. 2003, Spec. No. 59-190
2. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM: The link between fungi and asthma - a summary of the evidence. Eur Respir J. 2006, 27 (3): 615-626. 10.1183/09031936.06.00074705.
3. Denning DW, O'Driscoll BR, Powell G, Chew F, Atherton GT, Vyas A, Miles J, Morris J, Niven RM: Randomized Controlled Trial of Oral Antifungal Treatment for Severe Asthma with Fungal Sensitization: The Fungal Asthma Sensitization Trial (FAST) Study. Am J Respir Crit Care Med. 2009, 179 (1): 11-18. 10.1164/rccm.200805-737OC.
4. Sporanox data sheet. http://medsafe.govt.nz/profs/Datasheet/s/Sporanoxcap.htm
5. Tucker RM, Haq Y, Denning DW, Stevens DA: Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother. 1990, 26 (4): 561-566. 10.1093/jac/26.4.561.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献